Piper Sandler analyst Biren Amin assumed coverage of Kalaris Therapeutics (KLRS) with a Neutral rating and $3 price target The firm says the preclinical data for the company’s anti-VEGF, TH103, do not offer differentiation when compared to the standard of care in retinal diseases. Piper is on the sidelines pending better clarity on TH103’s clinical profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: